ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on the development of ocular treatments has announced that the Belgian tax authorities have granted the company a positive ruling under the “patent income deduction regime”. The Belgium-based incentivisation scheme should allow ThromboGenics to benefit from a reduced tax rate for all patent related income arising from the company’s lead ocriplasmin product. On July 27th, the company announced it had received a US Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee recommendation that ocriplasmin be approved for the treatment of symptomatic vitreomacular adhesion (VMA).
ThromboGenic’s ocriplasmin revenues may benefit from Belgian patent income treatment
- by swdadmin